PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24239912-0	2014	Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.	Ruthenium(II)	30-43	poly(ADP-ribose) polymerase 1	Homo sapiens	93-122	
32768729-0	2020	Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells.	Ruthenium(II)	96-109	poly(ADP-ribose) polymerase 1	Homo sapiens	38-42	
32768729-2	2020	Based on the rational drug design, derivatives of PARP inhibitor 3-aminobenzamide (3-AB), 2-amino-4-methylbenzamide (L1) and 3-amino-N-methylbenzamide (L2), were coordinated to the ruthenium(II) ion, to form potential drugs affecting DNA and inhibiting PARP enzyme.	Ruthenium(II)	181-194	poly(ADP-ribose) polymerase 1	Homo sapiens	50-54	
32768729-2	2020	Based on the rational drug design, derivatives of PARP inhibitor 3-aminobenzamide (3-AB), 2-amino-4-methylbenzamide (L1) and 3-amino-N-methylbenzamide (L2), were coordinated to the ruthenium(II) ion, to form potential drugs affecting DNA and inhibiting PARP enzyme.	Ruthenium(II)	181-194	poly(ADP-ribose) polymerase 1	Homo sapiens	253-257